PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Legend Biotech Corporation (LEGN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US52490G1022

CUSIP

52490G102

Sector

Healthcare

IPO Date

Jun 5, 2020

Highlights

Market Cap

$6.36B

EPS (TTM)

-$1.92

Total Revenue (TTM)

$520.18M

Gross Profit (TTM)

$316.00M

EBITDA (TTM)

-$301.26M

Year Range

$32.66 - $70.13

Target Price

$82.00

Short %

24.79%

Short Ratio

14.54

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
LEGN vs. COST LEGN vs. ADVM
Popular comparisons:
LEGN vs. COST LEGN vs. ADVM

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Legend Biotech Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%80.00%100.00%JulyAugustSeptemberOctoberNovemberDecember
-8.19%
83.85%
LEGN (Legend Biotech Corporation)
Benchmark (^GSPC)

Returns By Period

Legend Biotech Corporation had a return of -43.54% year-to-date (YTD) and -45.00% in the last 12 months.


LEGN

YTD

-43.54%

1M

-9.22%

6M

-16.08%

1Y

-45.00%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of LEGN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-8.49%18.34%-13.92%-22.02%-8.53%10.70%27.32%2.06%-15.33%-7.61%-6.55%-43.54%
20231.16%-8.55%4.42%42.49%-6.61%7.57%9.40%-8.16%-3.16%-1.64%-7.95%-1.07%20.53%
2022-8.52%-7.15%-8.21%10.48%5.33%30.05%-14.11%-1.59%-12.24%22.11%3.39%-3.09%7.10%
2021-10.26%7.56%6.77%3.72%30.80%4.27%4.82%-11.02%32.04%3.84%-1.89%-9.51%65.52%
202015.03%-17.20%-3.52%-9.21%-16.20%14.92%-5.28%-23.89%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of LEGN is 6, meaning it’s performing worse than 94% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of LEGN is 66
Overall Rank
The Sharpe Ratio Rank of LEGN is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of LEGN is 77
Sortino Ratio Rank
The Omega Ratio Rank of LEGN is 99
Omega Ratio Rank
The Calmar Ratio Rank of LEGN is 66
Calmar Ratio Rank
The Martin Ratio Rank of LEGN is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Legend Biotech Corporation (LEGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for LEGN, currently valued at -0.96, compared to the broader market-4.00-2.000.002.00-0.961.90
The chart of Sortino ratio for LEGN, currently valued at -1.42, compared to the broader market-4.00-2.000.002.004.00-1.422.54
The chart of Omega ratio for LEGN, currently valued at 0.84, compared to the broader market0.501.001.502.000.841.35
The chart of Calmar ratio for LEGN, currently valued at -0.80, compared to the broader market0.002.004.006.00-0.802.81
The chart of Martin ratio for LEGN, currently valued at -1.58, compared to the broader market0.0010.0020.00-1.5812.39
LEGN
^GSPC

The current Legend Biotech Corporation Sharpe ratio is -0.96. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Legend Biotech Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.96
1.90
LEGN (Legend Biotech Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Legend Biotech Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-55.59%
-3.58%
LEGN (Legend Biotech Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Legend Biotech Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Legend Biotech Corporation was 56.85%, occurring on Dec 16, 2024. The portfolio has not yet recovered.

The current Legend Biotech Corporation drawdown is 55.59%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-56.85%Jul 31, 2023349Dec 16, 2024
-45.56%Oct 12, 2021106Mar 14, 202277Jul 5, 2022183
-44.67%Jul 1, 2020170Mar 4, 202194Jul 19, 2021264
-32.84%Jul 6, 202259Sep 27, 202275Jan 13, 2023134
-28.01%Jul 23, 202120Aug 19, 202129Sep 30, 202149

Volatility

Volatility Chart

The current Legend Biotech Corporation volatility is 16.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
16.72%
3.64%
LEGN (Legend Biotech Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Legend Biotech Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Legend Biotech Corporation.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab